ANAB - AnaptysBio, Inc.
AnaptysBio, Inc. , a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.
As of Jun 30, 2026: spot at $67.74, ATM IV 90.5%, max pain $60.00, net GEX $18.9K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $2.72B
- Beta
- 0.41
- 52-Week Range
- 11.404-72.36
- CEO
- Daniel Faga
- Employees
- 104
- IPO Date
- Jan 26, 2017
- Exchange
- NASDAQ
What ANAB Looks Like to Options Traders Today
IV rank of 30.8% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($18.9K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (0.101) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The ANAB overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked ANAB overview questions
- What is ANAB?
- ANAB is the ticker symbol for AnaptysBio, Inc., a listed security. AnaptysBio, Inc. , a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. Listed on NASDAQ. ANAB is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the ANAB options snapshot look like today?
- As of Jun 30, 2026, the ANAB options snapshot shows spot at $67.74, ATM IV 90.5%, IV rank 30.8%, max pain $60.00, net GEX $18.9K, expected move 25.95%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are ANAB's key statistics?
- AnaptysBio, Inc. (ANAB) carries a market capitalization of $2.72B, beta of 0.41 relative to the broader market, 52-week range of 11.404-72.36. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does ANAB belong to?
- AnaptysBio, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare ANAB's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the ANAB data on this page?
- The options snapshot above is dated Jun 30, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).